ALMATABIO
AlmataBio is a developer of a humanized monoclonal antibody intended to bind to interleukin-1β with high affinity and neutralize its activity. The company specializes in antibody that effectively prevents hidradenitis suppurativa and various inflammatory diseases in dermatology, gastroenterology, and rheumatology.
ALMATABIO
Industry:
Biotechnology Health Care
Address:
Atlanta, Georgia, United States
Country:
United States
Website Url:
http://www.almatabio.com
Status:
Active
Official Site Inspections
http://www.almatabio.com
- Host name: a2aa9ff50de748dbe.awsglobalaccelerator.com
- IP address: 3.33.130.190
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "AlmataBio"
AlmataBio - Crunchbase Company Profile & Funding
Mar 27, 2024 AlmataBio is a developer of a humanized monoclonal antibody intended to bind to interleukin-1β with high affinity and neutralize its activity. The company specializes in antibody …See details»
AlmataBio Company Profile 2024: Valuation, Investors ... - PitchBook
AlmataBio was founded in 2023. Where is AlmataBio headquartered? AlmataBio is headquartered in Atlanta, GA. What industry is AlmataBio in? AlmataBio’s primary industry is Drug Discovery. …See details»
AlmataBio - Products, Competitors, Financials, Employees, …
When was AlmataBio founded? AlmataBio was founded in 2023. Where is AlmataBio's headquarters? AlmataBio's headquarters is located at 650 Ponce De Leon Avenue, Atlanta. …See details»
AlmataBio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
In addition, Avalo’s acquisition of AlmataBio, Inc. was accounted for as an asset acquisition resulting in the recognition of $27.5 million of acquired in-process research and development …See details»
Almatabio Inc. Company Profile | Atlanta, GA - Dun & Bradstreet
Address: 650 Ponce De Leon Ave NE Ste 3001489 Atlanta, GA, 30308-1804 United StatesSee details»
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement …
Mar 27, 2024 AlmataBio was founded to identify, acquire, and accelerate the development of clinically meaningful therapies, and we are proud of the contribution of the talented AlmataBio …See details»
Avalo Reports 2023 Financial Results and Provides Business Updates
On March 27, 2024, Avalo acquired AVTX-009, a Phase 2 ready anti-IL-1β mAb, through an acquisition of AlmataBio, Inc. The consideration included stock valued at $15 million, as well …See details»
Document - SEC.gov
AlmataBio, Inc. (the “Company” or “AlmataBio” or “we”) is a biotechnology company that was incorporated on April 28, 2023 (date of inception), with primary operations largely limited to …See details»
Avalo Therapeutics acquires AlmataBio - 2024-03-27 - Crunchbase
Mar 27, 2024 Acquired Organization: AlmataBio AlmataBio specializes in antibody that effectively prevents hidradenitis suppurativa and various inflammatory diseases. Acquiring …See details»
AVTX - Avalo Acquires AlmataBio and Agrees to Private...
Mar 28, 2024 Patrick J. Crutcher, former CEO of AlmataBio, added, “We are pleased that Avalo recognizes the promise of AVTX-009, an important potential treatment option for patients with …See details»
Avalo Therapeutics Shares Triple After Acquisition of AlmataBio ...
Mar 27, 2024 Avalo Therapeutics, Inc. acquired AlmataBio, Inc. for $42.5 million. Mar. 27: CI Avalo Therapeutics Shares Triple After Acquisition of AlmataBio, Private Placement Financing …See details»
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement …
Mar 27, 2024 Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected …See details»
Avalo snaps up AlmataBio for ex-Lilly inflammatory drug - Fierce …
Mar 28, 2024 Avalo Therapeutics is handing over more than $22 million in stock and cash to acquire AlmataBio for a phase 2-ready monoclonal antibody for hidradenitis suppurativa (HS). …See details»
Avalo Acquires Anti-IL-1β mAb and Announces Private ... - BioSpace
Mar 27, 2024 AlmataBio was founded to identify, acquire, and accelerate the development of clinically meaningful therapies, and we are proud of the contribution of the talented AlmataBio …See details»
Avalo Raises $185M for IL-1β Antibody Through Private Funding
Apr 2, 2024 Avalo Therapeutics, Inc. has announced the procurement of a monoclonal antibody targeting IL-1β, designated as AVTX-009, which is prepared to enter Phase 2 trials.This was …See details»
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement …
Mar 28, 2024 AlmataBio was founded to identify, acquire, and accelerate the development of clinically meaningful therapies, and we are proud of the contribution of the talented AlmataBio …See details»
AlmataBio Acquired by Avalo Therapeutics For $22.5 Million
Apr 3, 2024 The Life Sciences team advised AlmataBio on its acquisition by Avalo Therapeutics (Nasdaq: AVTX). The transaction was structured as a stock-for-stock transaction whereby all …See details»
Avalo Snags Former Eli Lilly Asset and $185M in Major ... - BioSpace
Mar 29, 2024 Pictured: Close-up of a skin lesion in a patient with hidradenitis suppurativa/iStock, krblokhin Avalo Therapeutics made a significant strategic pipeline decision Wednesday, …See details»
Avalo secures novel anti-inflammatory drug in AlmataBio buyout
Mar 27, 2024 The acquisition was structured as a stock-for-stock transaction, with AlmataBio's equity interests exchanged for a combination of Avalo common stock and non-voting …See details»
Micro-Cap Avalo Therapeutics Stock Rallies As It Snaps AlmataBio …
Mar 28, 2024 Avalo Therapeutics Inc (NASDAQ:AVTX) shares are skyrocketing as the company on Wednesday announced the acquisition of a Phase 2-ready anti-IL-1β mAb, which it refers …See details»